NZ591908A - Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma - Google Patents

Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Info

Publication number
NZ591908A
NZ591908A NZ591908A NZ59190806A NZ591908A NZ 591908 A NZ591908 A NZ 591908A NZ 591908 A NZ591908 A NZ 591908A NZ 59190806 A NZ59190806 A NZ 59190806A NZ 591908 A NZ591908 A NZ 591908A
Authority
NZ
New Zealand
Prior art keywords
expressed
compositions
methods
cancer cells
immune responses
Prior art date
Application number
NZ591908A
Other languages
English (en)
Inventor
Adrian Bot
Zhiyong Qiu
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of NZ591908A publication Critical patent/NZ591908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ591908A 2005-06-17 2006-06-16 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma NZ591908A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69157905P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
NZ591908A true NZ591908A (en) 2012-09-28

Family

ID=37325697

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591908A NZ591908A (en) 2005-06-17 2006-06-16 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Country Status (14)

Country Link
US (2) US7999088B2 (de)
EP (3) EP2385060A3 (de)
JP (1) JP5416968B2 (de)
KR (1) KR20080026181A (de)
CN (1) CN101198620A (de)
AU (1) AU2006259220C1 (de)
BR (1) BRPI0611794A2 (de)
CA (1) CA2612516C (de)
ES (1) ES2413079T3 (de)
IL (1) IL188113A (de)
MX (1) MX2007015933A (de)
NZ (1) NZ591908A (de)
SG (1) SG162817A1 (de)
WO (1) WO2006138567A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
JP2008526764A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 免疫応答の誘導におけるｃｄ４＋細胞の回避方法
AU2005321940B2 (en) * 2004-12-29 2012-04-19 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US8084592B2 (en) * 2005-06-17 2011-12-27 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP2371850A3 (de) * 2005-06-17 2012-08-01 Mannkind Corporation Epitopanaloge
EP2385060A3 (de) 2005-06-17 2012-02-15 Mannkind Corporation Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
JP2009544610A (ja) * 2006-07-14 2009-12-17 マンカインド コーポレイション 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
CA2996732C (en) 2007-03-26 2020-10-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
EP2148697B1 (de) * 2007-05-24 2012-10-03 GlaxoSmithKline Biologicals S.A. Lyophilisierte wt-1/cpg zusammensetzung
EP2490713A2 (de) * 2009-10-23 2012-08-29 MannKind Corporation Krebsimmuntherapie und behandlungsverfahren
EP4285922A1 (de) * 2011-05-26 2023-12-06 Geneius Biotechnology Investments, LLC Modulierte immundominanztherapie
RU2554821C1 (ru) * 2014-02-18 2015-06-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения Российской Федерации" Способ оценки степени локальной холодовой травмы в раннем реактивном периоде
EP3400004A1 (de) * 2016-01-08 2018-11-14 Vaccibody AS Therapeutischer antikrebs-neoepitop-impfstoff
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
CN106367406A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 Udp糖基转移酶免疫原多肽及其用途
CN106581668B (zh) * 2016-12-31 2020-03-24 广州姿生生物科技有限公司 一种抗原表位肽组合物及其应用
CN112686128B (zh) * 2020-12-28 2022-10-14 南京览众智能科技有限公司 基于机器学习的教室课桌检测方法
TW202309071A (zh) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 特異性結合ｐｒａｍｅ之抗原結合蛋白

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1757694A3 (de) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostata-spezifisches Membranantigen
US5747271A (en) 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5610013A (en) 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US6013481A (en) 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5858689A (en) 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5512444A (en) 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US5512437A (en) 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5837476A (en) 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5856136A (en) 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6548064B1 (en) 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6287756B1 (en) 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
DE69834494T2 (de) 1997-07-10 2007-03-01 Mannkind Corp., Valencia Vorrichtung zur induktion einer ctl-antwort
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US5888751A (en) 1997-07-15 1999-03-30 Ludwig Institute For Cancer Research Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US5985571A (en) 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
HUP0103976A3 (en) * 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
ATE440960T1 (de) 1999-02-05 2009-09-15 Univ Melbourne T-helferzellen-epitope
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
US6720146B2 (en) * 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
EP1118860A1 (de) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Verfahren zur Auswahl und zur Herstellung von T-Zellen-Peptidepitopen sowie darauf basierten Impfstoffen
CN1452634A (zh) * 2000-02-23 2003-10-29 埃皮缪纳股份有限公司 Hla结合肽及其用途
EP2248910A1 (de) 2000-04-28 2010-11-10 Mannkind Corporation Epitope-Synchronisierung in Antigen presentierenden Zellen
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP2295074A1 (de) 2001-03-07 2011-03-16 Mannkind Corporation Anti-Neovaskulatur Präparationen zur Krebsbehandlung
US20030044813A1 (en) 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002086071A2 (en) 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US6706405B2 (en) 2002-02-11 2004-03-16 Analytical Services & Materials, Inc. Composite coating for imparting particel erosion resistance
US6715905B2 (en) 2002-06-17 2004-04-06 Birchwood Products Limited Lighting apparatus
WO2004005891A2 (en) 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
JP2005537800A (ja) 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列
EP2356999A1 (de) 2003-06-17 2011-08-17 Mannkind Corporation Zusammensetzung zur auslösung, verbesserung und erhaltung von Immunantworten gegen MHC klasse -I-beschränkte Epitope, für prophylaktische oder therapeutische zwecke
EP2338506A3 (de) 2003-06-17 2011-10-12 Mannkind Corporation Kombinationen von tumor-assozierten antigenen zur behandlung von verschiedenen krebstypen
US20060159689A1 (en) 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP5166025B2 (ja) 2004-06-17 2013-03-21 マンカインド コーポレイション エピトープアナログ
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005265181A1 (en) 2004-06-17 2006-01-26 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
JP2008526764A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 免疫応答の誘導におけるｃｄ４＋細胞の回避方法
AU2005321940B2 (en) 2004-12-29 2012-04-19 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321904B2 (en) 2004-12-29 2012-07-12 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2371850A3 (de) 2005-06-17 2012-08-01 Mannkind Corporation Epitopanaloge
EP2385060A3 (de) 2005-06-17 2012-02-15 Mannkind Corporation Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
US8084592B2 (en) 2005-06-17 2011-12-27 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
JP2009544610A (ja) 2006-07-14 2009-12-17 マンカインド コーポレイション 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
EP2129389B1 (de) 2007-02-15 2014-10-08 MannKind Corporation Verfahren zur verstärkung der t-zell-antwort
EP2152890A1 (de) 2007-05-23 2010-02-17 MannKind Corporation Multicistronische vektoren und verfahren zu deren konstruktion
KR101718768B1 (ko) 2009-12-21 2017-03-22 삼성전자주식회사 휴대용 단말기에서 전력 소모를 줄이기 위한 장치 및 방법
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (de) 2018-10-12 2021-04-28 Liko Research & Development AB Tore mit übergangsrampen für deckenhubschienen

Also Published As

Publication number Publication date
SG162817A1 (en) 2010-07-29
CA2612516A1 (en) 2006-12-28
EP2385059A3 (de) 2012-02-15
EP1896494B1 (de) 2013-04-03
WO2006138567A3 (en) 2007-02-15
AU2006259220A1 (en) 2006-12-28
EP2385060A2 (de) 2011-11-09
CA2612516C (en) 2015-03-24
WO2006138567A2 (en) 2006-12-28
AU2006259220C1 (en) 2013-05-16
US7999088B2 (en) 2011-08-16
IL188113A0 (en) 2008-03-20
KR20080026181A (ko) 2008-03-24
JP2008543315A (ja) 2008-12-04
EP2385060A3 (de) 2012-02-15
CN101198620A (zh) 2008-06-11
IL188113A (en) 2015-03-31
EP2385059A2 (de) 2011-11-09
US8674081B2 (en) 2014-03-18
US20110269949A1 (en) 2011-11-03
BRPI0611794A2 (pt) 2010-09-28
US20070004662A1 (en) 2007-01-04
EP1896494A2 (de) 2008-03-12
ES2413079T3 (es) 2013-07-15
AU2006259220B2 (en) 2012-10-11
MX2007015933A (es) 2008-04-21
JP5416968B2 (ja) 2014-02-12

Similar Documents

Publication Publication Date Title
NZ591908A (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
ATE439375T1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
NZ716587A (en) Antibodies specific for claudin 6 (cldn6)
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
CY1110187T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
WO2004022709A3 (en) Epitope sequences
JP2004537252A5 (de)
HK1039749A1 (en) Use of expressions of ctl and t-helper lymph cellsin vaccination
DK0677533T3 (da) Antistoffer mod epitoper med homologi til selv-antigener, fremgangsmåder til fremstilling og anvendelser deraf
NO20072253L (no) Forbedrede vaksiner
MXPA05014152A (es) Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
IL163851A0 (en) Internalizing anti-cd74 antibodies and methods of use
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
IN2009CN03372A (de)
JP2013507970A5 (de)
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
WO2007149518A3 (en) Dna composition against tumor stromal antigen fap and methods of use thereof
DK0880360T3 (da) Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
Taubman et al. Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries
EP1556513A4 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 JUN 2013 BY JAMES + WELLS

Effective date: 20130222

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 JUN 2016 BY JAMES + WELLS

Effective date: 20130225

LAPS Patent lapsed